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Abstnwt 
'This paper reviews b;>sic concepts of m~-nstrual disorder:; in 
.adolescents bcgin.,.'ling with a:n overvi!:W of memstmai 
phy~idogy followed by consldcr~tion of variuus abnormal 
menstruaJ patterns: amenqrrhea (primary und secondary)., 
dysflmctlonal uterine bleeding, dysrMnorrheil (_primary and 
secondary), and premenstn1al syndrome. 
Keywords: Adolescence, fem;Jle, menstrLtaLion 
Introduction 
Menarche, or the onset of menstmation, occurs on 
average at 12.7 yeats of age in American female~ 
(approximately ] 2. 16 yeafs in African-American 
females v~rsus 12.88 years in Cau.cac;[an females} (1 ). 
A respons-ive H~P~O (hypotha1amk-pituitaty-ovarian) 
ax,is induces cyclkai menstruation that is regulated by 
lev(:!.ls of cstrog~n and progesterone and result'3 in 
three classic menstrual phases: foWc1.1lar, ovulatory, 
and luteal (4) . Regulation of the onset and regularity 
of menses is tmder ffi:lny influences, as listed in Table 
1 ( 4 ). The level of cxcrcl~e in adolescents involved In 
spotts can have tcnJ.sid.erable in:i1ucnce on their 
menstrual patterns (5). 
Ad.olescent mm1st:rual patterns 
The menstrl.1al pattern of a mature fetmtle adult has a 
mean interval of 28 days (+/- 7 days) and. a m,edian 
blo0d loss of 30 ml per .month, with 60-·80 mL per 
month often set as upper limits of nonnal blood loss 
(6). There ~s more variabil ity in the adolesce11t female, 
often due to lack of regular ovubtio.n for several 
months to several years after menarcne. 
Approximately half of her cycles are anovulatory in 
the fi rst two years after m~narcbe and 20% are still 
without ovulation by the fifth menstrnal year. 
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Table 1. Inflt~encc~ oo the Menstrual Cyde 
!""""""'"-- --···--····-·-···---··-··---·-·- ------....... ~ A.gc , 
ivhight and Height ! ~h.y~i.ologi. c· and sex. d~.:V;:l!)pment sychoiugical stress N'-ltritiona1 dcfici~nt.ics r<:neti(: prcdispositio.n 
r~n:er:t body lilt 
~'mount of exerri~e "h:on!c IHn~ss t.'ledicatiOI'S {prcscn ptit'll Gr owr Uu: counter) Race 
I ) th(.lfS ----------- .. ·-------------
The medi<m cycle length for adolescent .females is 
31 days in the first two y~ars after menarche:, in 
ctmtrast w 2& days for the adu.lt female. 
Approximately 38% of cycles crt 2 years after 
menarche are less than 40 days. This classic !a.;.-,k of 
ovulation in the adolescent female may result ill 
oligomenorrhe~, arr\enorrhea or dysfunctional utel'ine 
bleeding. Definitions of menstrual abnormaLiti((S ate 
noted in Table 2. Menstrual disorders discu~s .ed b~low 
include am<;norrhea, dysfunctional uterine bleeding, 
and dysrnenorrhca.. 
J':1hlc 2. :ilcu.:>!:nml Disor:ders Delin.Hinns* 
~·····.···- 1 . . -.;·· ··; ·-.---.~----.···---- ·-------·-···········---------·-----·--·---- ---·····--·-··•...., 
:1. Normar Adult Menstrucu .Cycle: : 
a. Mean interval of28 days (i 7 days) 
b. Duration of menses of4 days (±2--3 days) 
c. Median blood loss is about 30 ml per month (with the 11pp~r .limit of norma! 
defined as 60-8.0 ml per month) 
Amencwrhea. Absence of menses; can he Primary or Secondary (absence of thrct} consequent men~trual: 
cycles, after regular periods hav!~ been established) 
Oligomenorrhea: Infrequent, i::Tcgular bleeding at >45-day intervals 
Menorrhagia: Pr~">tonged (>7 day:;) or excc~sive (>·80 rnJ) uterine bleeduog occurring at regular intervals 
]!,f et>·orrhag ia: Uterine biecding occuning at irreguiar hut frequent intervals, the ammmr being variable 
lvlenometrorrhagia: Prolonged uterine bleeding OGcun·i11g at kregular in!.crvals ;,:' 
Hypemu:.norrhea: Synonyrncus '>Vith menorrhagia 
i~_ Polymenorrhea: Uterine- blecdirig occurring at regular intervats of <21 days ~: l);~if_unclional Uterine ~l~e~ing: .abnormal (different from that patient's nonna!) uterine bleeding that is 
l__~::n:;ated to any <:natumH; .leswn . 
"'"' Rcpri;t~~!, with permission, -f~~-m·::·-Greyda,"lus ·-D'i:~ Breast and Gynccologi~ii Diso~d-~~~-.- In: Adolescent Medicl~e. 
3'rl Edition. Eds: AD Hofmant; and DE Grcydar.us . Stamford, CT: Appleton and Lange, ch. 25: page 547. 1997. 
.Amenorrhea 
The ab.sene-e of menses is called arnenorrhca, and is 
defined as primary or secondary amenorrhea (7,9). 
The defini tion of primary amenorrhea is th~ abse-nce 
of menstruation by 14 vears of age with a sexuallv 
• ~ J 
maturity rating (SMR) of l or by I 6 yeats of age at a 
SIVIR of 2 or greater. Once rn~ns~s has started, t:.'J.~ 
lack of periods for three cyck s ol' for 6 months 
defines secondary am,enorrh~a. Oligomenorrhea refers 
to inJi:eqlwnt, irregular menstrual bleeding wlt.h 
greater than 45 day cycles. Aithough a.:-nenorrhea can 
be normal i;1 the adolescent for three to six months 
during t..l:c first two years after menarche, a number of 
medical conditions can he the cause for an a,dolescent 
presenting with amenorrhea (primary or secondary) or 
oligom~norrhea (see T ables 3 and 4) . Tables 3, 5, 6 
list various. laboratory tests useful in this clinical 
ev<uuation . The most common cause of secondary 
amenorrhe4 j~ pregnil:tcy. Once pregnancy has been 
ruled ouL, laboratory testing >viti eliminate or confim1 
_hyothyroidisrn and hyperprcla(:tinemia as potential 
diagnoses. It is important to co ;~ s ider the remaining 
cau~es of secondary c.melion:hea classified as 
normogonadotropic amenorrhea, ·hypogonadotrnplc 
hypogonadism, a;;d hypergonadotropi~ 
hypogonadism, each having specific etiology. The 
most common causes o f norrnogonadotropic 
a menorrhea . arc outflow ob.struc1ion and 
hyperandrogenic chronic anovulation. PGlycy:;tic 
ovarian syndrome (PCOS) is the most common cause 
of hype:randrogenic chronic anovulation. The high 
prevalence of secondary arnenorrhea S(~cn in 
adolescent athletes w-arrants funher d.b:-.ussion. 
.. ...................... ... ------------------~ 
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Tal:lte 3. GynccolQgicai dhorders of s&dolcsccut fcm:dcs 
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Gynecologic __ ... ]s'P;;;i·afcommenN to,, ;frcr<mt'i~TZ;·i-~g~i·.;;;·i~ ......................................... ~.:,: l~aho~~;i;;.;, testing ! 
!sordct j , ! 
t\m~norrhca !P1!ysio.iog.ic:·;~·i:r.;;; ·rn.ai ii .. ~a't;$;;· .................... 1>hy:si:Aogic jSc!:Un1·-g;i;;·(J;t~pi;-s------; 
KPr[mary) ~.1RK1 I syndrome ass~;c , ~:i th Renai ~rnp~rJora.te hymen [{FSH, LH}. prolat;tin, 
i !abnormalities and Spital maJfonnations l;v1ayer-Rokitansky-Kuster-Il auscr tfSH; 
! ~hort starun: with dt·lay~d st~xual ~MRKf!) Syndron:c; bei~ic U ltras!~und MR l, 
J ~~laturatil,n: Tmner syndrome: delayed [rurno syndrome (45,XO .::nd mosaicism) l lead CT!MIU Rena! 
i !>cxual m.atHration ,. hype~rknsion seen !n :hwnic Illness ltmsnundrTVP 
1 ·:yndrome; ab~e."l.cc ot smd! sens~ ·xerc1se, depress!on; Ka1-yotype 
'Uggr:~ts Kallmann syndrome: vi;ual field Androgen insensitivity :-yndmme ( 46 X'Y); lLa.paroscopy 
'eficits sugg(;~::s bra!n tumor. S'.Ny er ;;yndrmnc; o thers : s~c T,:xt ! 
!----,-- -- - .. ............. . ._ ........................................................... - ·-·---------; 









1~exual activity-- m;,y present w ir.h a fStH;;s~, eating d1sorders. ji'est (~--hCG) i ~nic!Hne ''pelv ic mass". c:mscs of !Chrunic illnes~, JProgl~~lerune. ctmUengc ! 
:01ifNnlcnorrhca a;;d secondary ~x•:rcise-induced, ~~i~nan estrogen, ~'Sl l, U I; i 
~mcnorrht:-<1 an:: _es'it:.nlially lh~ same. A!so ~m:<hldinoma (beadaches, visilal Jkld ~one mineral l ~mpurtant is histosy of dietat-y hnhi:ts, ~dicit.s, galactorrhea) ~·::nsitometry; ! 
~XC. n .'.lS.C, .S.tr.e,~S: . ac. r.e.ana.' hiJ_·~utlS1)1. lJ'_('(}S (polycystic OVary syndrome); -·.Cn.l.!ll prolactin. ! ~ugg~·~t elevated androgen )evl~l"; .Ath!etc [s(~e text . hytuid ~;creet;; i 
' . . t . I 
tl.rl¥1 Syndrome: amenorrhc:a, i Head CT ! 
' ' I [dysfunctional eating pilltt:rns, ostc~;pcnia- j i 
~""1JSiS 1 i i y~·l;~~;_~;;:he~ -~~-~ivTc:~;ai n dming nom: a J. ~-i~ysioi0'g;c"'"''""'""'"'"'"""'"'""""'""'" : . 
i (P.riinn..t·y) fJVul;~tory mcnsi.nmlwn; .no linderlyin~ ; l 
pysnJencmhca 






pclv;c p!Hholngy. iEndomt~triosis ~--aparoscopy 
jY1uy H!so see gastmihtestinai sympt0ms, ~c!.vi ~,: Ir!lJammatmv Disease ~TD screen 
U
1
'leudachc, myaigia, sweating. ~eprodlictive tract ~O!t:aiies iflel'vic Uil:rasour:d; MR l 
! i \Pelvic adhesions i 
[May be. seen lit rnewrche or 3+ ye~rs \Ce'vicai stenosis 1 
'!P ' ""'ll''"-he .'·'o•.-~;·> · n nl'<t~se~ 1 
· t:lvic: torge~tion syndrome ! 
· uie out Urinary Tract o r· I 
JasJ:rn!ntcstinal causes . 
!,:':, o :;:,·:•ut:. ,,., "·" . '~ ,~ -- - I 
·....,-----.;--· ·-+ - -------,.--,.---,.-- ------·----<---.. --------------· fcnsi~:~ai -~zicndar.lisc'ftii"to.get.acc~:lr.atc .ncY\llatory b!eecting; FBC, platelets, aet•l-i Jysf-;:mctionat 
,rtcrinc 
'k>:ding 
,istory of me1tstmal pattern; get scxu:~i •>regnancy, ectopic pregnancy; C:o<'.g>Jla•ion [HCG, Pap sme(lr, !)T, 
J.ctivi.ty history; jdisorders (as von \Vi!kbrand disease, rTT, bked!ng time,. other 
bstablish presence/absence of ovui;itioil: bthcrs), anatomic lesions, em!ametrikll !c t)agu.latiml disordc: rs. 
I . : 
hasal body lert:perature duns, serum [p"tholugy; cervidtis or cervical dysplasia; !~crccning; D-21 
rogestetone, uritli!rV hiteiafzin0" ho;·rnonc:i:::d vic it)_{la, .. nmatorv di se~;;e: ovarian cvst.-; ·, lurog;:sterom;: thvruid i"' • . ~ ?- .I ' ,I :J:: ~- ' .I 
kLH) and pMs-ihly cndomerrial biopsy. jpolycy~tic ovary syndrome; scvc:rc >ircss, ~;,;r~cn; STD screen; 
ir.tie out an STD; v i. riiization cva!uHtion lrnr!d or severe weight ga}n or less, drug iultrasm.Jnd. (trru~waginal; 
bcce·ssary if l-iirsUiism prc5cnt. bbuse; sec text. . ~eh:ic ), MR I; ! 
J ,y~teroscopy. j 
jEctopic· tp;;;; .. ~;;;;;:f;-hi-str;-;:y·;;(~;;c'Or;;i'ary . ~kt.: iSfi}f'diti~·~:<;;it:iai_ .................................... ___  --:i1ct~-pr.l•i~; ·u t irasl)un;if 
!Pregnancy [am~norihee, .o!~en with vilg ina.l bleeding. j i I I i 
c-,---........... ~-t·-.. -----·------------------------------------------ . .. ......................................................................... L ; 
!End.omdriosi5 Prcl;cntati;}tl in adc.!e~cence not the same: pt~e secondary dysmenorrheal f!..aparoscopy ! 
1 · in adults. May hav1: acyclic: pa.in, ' ~':.~ . .. apa.roton:y i 
l h~(l"~a' u•·'r;r .. • bl ··-··"n" c"'r , .\ i! J.~u : . \."- "- :t.:.. l AA.lt !e,. .]... : ---.. -·-·-------------- symptomaiukigy .. , .......... L........ i ............................. ___ __! 
;. 
,' ~: : .·· 
: ... · 
,-···.-:.·;·:: 
::. : ~ :: 
:: . . : 
. .  ·' . . : ~ : ~ 
• .. •: .. •.· 
-··=--··.·-· 
:) ~ 
: . • 
:· .. · 
:- .. • 
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Table 3. (Continued) 
p;;~~0-ioiic ____ _ -;pe~Eti"co_n_u_r_,e_n_t_s _____ ·-········-··-.. ········ ····-··-··-··-··jti;#frcx;:::-t-ll-,-h-a-h"~:o&is __________________ ]Lati(;r;;i;;iY--!~;tiiig 
k; i s!"'rrsie.r i i f----------------------------· .......... --------------- ..... . . ----------------------------;;. ............... _.,.- ---········----·---·--
iMitt(':]Schmertz. Pat!; as:>Qcia)ed with ovubtion ill the middle lSce secondm·y ~V:enstnJa[ 
i ,fa menst.-:uai cycle. May la.~t ! -3 days r•smeoorrhi.:t! lcaienda.r 
i. nd. he. miki to scv~re. i . i 
! 
l --+~----$varr~;--··------- .rc~~cnt~--~~i.ti1 .a l~.total i(i~a!\0;~:--····-··-~- ---~------- --- ;·iv~ri~a-r-, _c_y_s.,.ts-· ---- ~regnan0~-i~st:--
~' -fa~scs -~lbtrormal menses . )varian tumors (ben·ign, !,.Pelvic Ultrasound 
i,, l, -11aligmmt) !
1 eoJy~-::ystic ovaxy syndrorne 
l i 
l tlctopjc l ';-cgnnncy 
! ; l'ill:Jo .. c;.vadan mass 
if'dvic ---+~::--1~'-=D-that.ca~~--i~ad to utcri;.(;"ie\-;a:;:..:ne:S:;,·-------- ~ct:op·i·c--ic-c-·v.r-. -;a_J_lc-}-',-i-lp-. f-,-e-n-:d::-!c:-it7is-,-t.N:c-:.,-o-n---s-p-c-:·dfk: 
jtnfl;l.rmnatory p.dnexai k nderne.ss, tcJH!erness en cervical yclonephritb, uvanar. cyst, Vili:tc: b!ond c~ns on ;;aline prep; 
!Di~ease jrn·::t ion, muco-p!.lru.lent va.ginal or c.ervk al ;epti.e ahorticm, others. kvatcd ESR; eievatcd CRP; iab 
klischarge; (;!lll see fevct (T > lO l F, ]lU C); ' Vid"n1.~e of Neisseria 
~~_,!ymicrahial disorder of the upper gc.nital 'onorrhoene or Ch!1.1mydia 
trad often pre.cip!takd by Neisseria 'rachorm.!lis; 
~~norrlwe:e, Chla.m:diu trachomatis, ot.."Jers. , "pccifk C£·it:eria 
u ardnerd;a vagln(!.l:s, Mycoplasma hommJs, 1 ·'osi>ive binp.~y: 
Urcaplasma urealyticum, Haemopbi!u~ [ Endometrium 
intlu~ nza.e,. coli!iJtms, cytom¢gaJovirus, i :ho-..:ving endometrt:is; 
eptostr\:ptoco<.~cus , and other anaerobes). ! :vidence nr PID on la.paros;.~opy: 
:an invoJyc varim;s· combinations of ! lltrasound or MRI showing 
!;,~ctomerriti:,, sa!pingttis, iub.cl-ovmian l ~.hut fi:llop'ian tubes ure th.kk and 
.bsccss, and odvic peritonitis. Comp!ications ! ~illed with t1uid; 
• " I I 
· r~cludci:nferr.illty, chronic pelvic pain, cctopic i jm;1y h~ J'tee !bid. in the pelvi~ IX 
.. I ' 
,.reg:nan.cy. i !a tuho-ovarian complex. 
• ••-•- ••••••••••u••••-• ooonoooooo ••·~·---------•-••• •••••• ••••n onoo• ••••- ••••-•••• ••••+ uooooo ,.,.. , 0 , 0 000 0000000 • •• • ••••• ••••4- ••• • •• • • • •• ••••. •••••••• • uou--- · -•-•••- •-•• • ••• (oly,;ysttc ·:nsuiin r~sistancc with hyperiru;u! im:mil~·, pthcr cause.s of [LH, FSH, T-4, prol~;ctin, 
p.v-;uy syr.cimmc~>ypemndwgcm:ml;;, anrl chronic anovul8.tioa; pypcrandmgerrism; HAJR-AN ~estoswmne (totai and free), 
rpc:os) hyper- r:an scr. i.rrego i'?" mc!EiCS c~econd~ry jSyndrs>:n~; Cong~nital ad~t:rHtl !inS\Ji)n k>vci; l.ipid ['lrtifik; 
lantlnlg<:r,cmw. p>m\~ normca., ollgumcnorrhea, DUB), ~1yperp!as1a (1113-nydroxymse, !~.lchydroepiandrosterc.tte s ;Jlf~l:c 
L<:yndrome. ~Jirsutis:n , possib'!e viriliz.atiorl, v ari~tble .... l-hydroxylase, KDHEJ\S); ! · phcs!l.y. <lCil."lthosis nigricans, possible B-hydrox:ysteroid d~hydr0gcnascj17-c:-hydroxyprogestcrone; 
i ~iiatcral CJ;Iargcrl ovaries. eficicm;y}; Cu;;hiag's diseas\:; 124 hour urine for (tee wrtiscl; 
! i ypetprolactinemia; Oval'lan or ~exarncthasonc su.ppressi;.m test; 
! i adren'l1 tumor; :Mi>:ed g.onadal [Pelvic ulL'<tsotmd 
' I ' ! i ivsgcnesis (45X/46XY.45X/ ! 
< I l ' . · . . ; ! ! !46XXJ46XY}; Gonada! dysgensisj 
i i ~\'ilh ~'rrilization; tnu:: ! 
I : ~ h .. . ! I j jJlo!n::tap ro>'lttsm 
~>te tm~:n~trual karit'.ty of"S)1i"lpt~mto ;;urt before ;md end wiih~1 re;n:t\!ns.tr~ai dysphoric disG:-der SM-IV p.ooo)'c~-E~:~~~--::J:_~.,-r -4 
jsyndrorne t•enscs KPMDD); c.kp1cssion; anxiety; VMDD 
r:~l.:~----············· ··············--- --- ----------·--······· -- · ·· "·"· ·······--·······--··J;~:~~t::~::~~~t~;-~~~ ;~=-~~----~- ---.. ···--.,-,.,----··----·········-··········-' Abbreviations: CBC; comp lete btcod. courrt; Pap: i•apanicolaou :,;mcar; SID.: sexpaHy transmitied disease; MRI: magnetic 
resonance imaging; CH: gHstrointcstinai; ESR: eryt.l-;rocyte sedimentatior; rate; F; Fahrenheit; C: Centigt~a.de; JiA1R-AX: 
hyperandrogenism, hirsutism, insulin resistance, acanthosis nigricar:s; DSM-lV: Di<lgnostic Statistical M.anual-4'h 
Edition (American :Psychiatric Assoc!<1tlon): PT: prothrombin time: l'TT: part ic..l thromboplas tin t ime. *Reprinted with 
permission from Grcydarms DE, :Feinberg AR, Patel DR, Homnick DN. eds. The Pediatric Diagnostic Examihation. 
New Yc.rk: McGraw-Hill , 2008. 
:···-··:- -:-:-_-:·:·-:·:·-:·:·-:·:· ···:· --:· · ·:··:·:··:·:·.-:·:·.-:·:-.•:·:•.•:·:•.•:·:·.·--=· · TTl! I II 1. 
--- ::· 





Adolescent female menstrua! disord({rs 361 
Tahl.c 4. CJini.cal .Classi:fknt ion nf Ame::w:rrhea iu tt~ A;lnl~st:~nt"' 
. . . 
!;·, Prima'>' !\ rncJ~O~~·i·;~;·~:·i·i1~"p~~be~t;T(se'~"r1~i~y·--·--·-··-.... -...... -. 
A . Gonadal matfimm1tion 
i. Turner syndrome {Gonadal dysg-.:nesis) 
1. Te~t.ict;;Jar fcminiztltion sy-~dron1c (m1dtogr.n ins~n~itiv~ty syndrome) 
B. Hypotha:lamiC-Pitu.lt:rry Dysfunction 
1 Physiologic i)elay {[\;lost tomn:.on} 
___ .. , ........................... ! 
; 
; 
2. F1~n<:tiona1 Disorders: hyporhabmic .. i!idueed: ~ \lch a~; wcightloss .. catb1g disordc1rs, exercise, stress,. c~thers 
.'l. Organ1c Disorders: Pralactinoma, Chronic-Illness, others 
1.. Primary Ame:KltThca Witho·:.~t Pubertal {Sex) Delay 
A. Pseudoamenorrhcil 
l . imperi\mH.e hymen 
2. Trans·ve:rse vagi~1ai o;ertum 
B. Mayer-Roldtn.nsky-l<nstcr-Hauser Syndmrne ·agenesis of vagina, cervix, ukn;:; 
C. Pvlycystic Ovary Syndrmnc-(Hypcrandrogcncmia Syndromes) 
! ; 
D. Chrnr.ic fHI1'.!:>S ( indudiiig 111yroid Disorder~) 
H Otbt:rs 
~H. Secondary Atm:mmhea 
i l. Preg:Jancy (inost rommor:) 
i 2. Hvpothalrur,Jc .. induccd such as Weight loss; <:atiag di~or(k:rs, cxercis<;._ stres~ 
j 3. P~lycysti.c Ovm-y Syndrom(~ (Hyp(:ril;1drogcnt.riiia Syndromes) 
j 4. Thyroid Dl;;orders 
5. Pituitilry disorders (!'ituitar;adenon'k'l) 
6. Hy pMstrogcnemia (ovarian dysfunction Ol' . ovari~n hypuf~mctim~.) 
7. Chronic Illness 
li . Others 
*~10Jified"a;~ct .. i:ep~i.~i~;·d·~~ith pt;rmissio;-r;;;-;;;·:-'G;~;'d,mtls D.E1 Patel. DR: The female athlete: before and be;;o-~d-pub-~tty. 
Pediatric: Clin:No Amer 49:553-580, 2002. 
'hhle 5. Meth(>ds tu :Evaluate B.ypBestrogenemi;e in 
Adolcs~::ents 
r----.,...--:----... - ............................................................. .. 
Physical and sex d~vclopm.ent 
(delay of sex development) 
Body weight 
Bone ntineral densitometry 
Sertl:tn. estra.dial lcvcl 
Va.gina! maturation index (VMI) 
Vaginal smear to evaluate for epithelial 
. cell estrogcnizatiot1 
'--·-·---.:::...-----------------
Amenorrhea in adolescent athletes 
AmenmThca and. otigomenorrhea are co.r. ... mon.ly 
encountered in the adolescent athlete population 
(1 O,J 1 ). Menarche may he delayed in an adolescem 
.athlete tive months for each year of intense, pre-
pubertal exercise. furthermore, secondary 
amenorrhea is wol 1-desc.ribed in ferna.le athletes 
participating in cyc!.lng, gymnastics, and rUJlOjng 
sports. Menstrual dysfunction is noted in 12% of 
swimmers as we!! as cyclfsts; 44% of baHct danc(:rs, 
50.% of female triathlctcs, 51% of endurance runners, 
and np to 20% of strenuously exercising females in 
genera! ( 12). Research suggests that up to 15% of an 
female athletes and two-thirds of ciite female athletes 
have menstrual dysfunction. As noted by Tablt! 1, 
tbt!I'C ate many factors influencing menstriJation in 
adolescent athletes. Tables 3 and 4 not~ the etiology 
of arn.enorrhea~ ·rnc. most con1mon ~~~use of 
amenorrhea in athletes involved \-Vith intcn~e excrdsi; 
is hypogonadotrop:c hypogonadism in 'iVhich there is 
Qysfunction of the GuRH production and LH 
pu!r.ativity. Low body fat, although is a factor, is .not 
lhe sole rcas{)n for menstrual dysfunction. The role of 
!eptin in the comp1cx menstrual pwcess is not yet 
clear. Previous theories implying that menstruat ion 
cannot occur below a body fat percentage of 17% arc 
not proven (12) . Low body \~\~ight by itself <i.oes not 
cause amenorrhea and the weight Q[ a fern ale athlete 
with no meilses can be the. same or even more that) 
one with a nonnal menstrual patten). 
>· •' 
···:· 
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T11~lc 6. Laba:ra!ory Testing for Amenonl!e:a 
in Adoh~§cents 
r:P;eg~~~;ty ·n:st . · ---······-··········-·--
! Hormona! invesrigation: 
·····-·-~ 
i 
1 ! . LH and .FSH: Jtwreaseci in o ..  .,raria.n i 
failure/dysgenesis; nonna1 or dccre(lsed in 
others 
Thyroid hormone levels 
Proiactin levels 
lf viri1i7,ation/hl~sutism present: DHE.l\S, 
LI1'FSH ratio (nl:<2.5: 1), 
testosterone (tot::>.! and free) 
Level of estradiol and progesterone and/Qr 
Vaginal smear to evaluate for epithdial cell 
estrogenizat.ion 






. Head CT/MRI l I Peividabrlominal MRI ! 
Renal ultrasoundilVP J'· 
L<l_r_~:.~~~copy -····················· .. ·-······-··------·-
Th~;: intense exercise pattern induces such a major 
en~rgy drain: that the caloric. intake of this athlete is 
not suff1cient to n1aintain normal menstrual functlcn. 
Meeting the energy needs of the athlete is tht 
cornerstone to restoring normal menstrual function. 
This treatment is further discussed. 
}danagement (?/'amenorrhea 
Tl:w managerr.ent of <tn adolescent. female. with 
amenorrhea or oligorm~norrhca is detennincd by the 
underlying canse(s) of the menstrual dysfunction. If 
an. intense exercise pattern is a central theme, lhe 
clinician can recommend a reduction in exercise by 
10% or more. Typically in the female athlete triad 
(i.e., irregular menses as amenorrhea, disordered 
eating, and osteopcn.ia:··· osteoporosis) (4), eating 
pe,tterns may be abnormal as wel.l, and she should be 
advised to improve her nutritional hitake, including 
calcium and vitami.n D supplei11entation. Com;u]tation 
'v'/tth a sports nHtrhionist <.:an help the- pc.tlent en~urc 
she is meeting the mltritional and caloric needs 
specifically during involvement in sports. If m£~nstrua1. 
dys(u.ncti"on is part of a chronic hypoestrogenemia 
(see Table 5), she is at increased risk for reducGd bm~e 
mineral density, osteopenla and eventually 
osteoporosis, Females with chrcnic lack of 
nJ(~nstruation and low hone· mineral density (BMD) 
rnay never acquire a normal HMD ~ven l:f the 
menstrual pattem event1.1ally is oortnalizec. 
Female athlet.es with low BlVlD an: at increased 
risk fm the development of st:·ess fractures. Daily 
supplementation with calcium (1000-1500 mg per 
day), Vitamin D (400-800 IU per day), Vitamin B 
Complex, and Vitan1in E (W0-200 IV per day) is 
recommended for this athlete with menstrual 
dysfunction and/or eating dysfunction ( iO). 
Approxima.tdy 50% of bOJJe mass is acquired during 
the adc1escent years, and thus, if the femaie 
adqlesL:ent athlete has a loW BMD, qstro~er1 
suppkmentation (conjugated estrogen or oral 
contraceptives) is suggested by many dinicia:;~ in an 
attempt to help her prevent hone loss. 
The American Academy of Pcdtatrics has 
recommended that the amenorrheic adole~:c~m athlete 
not be given hormonal medication if she is wi1J1in 
thr<~e )'$a.rs of menarche; instead, she should be 
advised to lmver lwr exercise pattern intensity and 
correct .her nutritional intake (i:nduding adequate 
calcium intake) ( 13). E strogen supplenwntati()n 
(typicaily the oral c.ontracept:ive) is recommended fQr 
the arnenorrhcic athlete if she is over 3 years from 
menarche and over age 16; hcrrn.ona1 rnanagement 
can used for thos.e under age i6 years, if there ls a 
history of a stres~ ti·acture. 
Hovv·evt~r, problems in the ma.'1agemc11l of these 
athletes often ari::ie. for example, many committed 
~thlctcs will not lower their intense exercise patterns 
nor altet their unhealthy dietary habits. Also, estrogen 
supplementation is Ci)ntrover!iial and. not pwven to 
enhance or protect BMD, with or without weight gain. 
rt is not cturently proven what the actual acute or 
chronic implications are of' chron.ic amenorrhea and 
potc~ntial estmgen deficiency in the female. adolescent 
athlete or in other females with these issues. 
The use of conjugated estrogen or the oral 
contraceptive doe.s not correct fhe tmderlying 
menstrual dysfunction and after the estrcgcn is 
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!\~SUrr(~S. There an:: also a number of potcntb;ll side-· 
effects to oral contraceptiws, including breast 
tcndcmcss, breast congestion, nausea, emesis, weight 
gain, and others. 
Some studies suggest that ora1 contraceptives 
under 50 meg estrogen may net be he'tphtl in 
preventing oskoporosis (4). BMD is usually the most 
rduccd in those who are thin and not active. Intense 
exercise invo!ving vveight bearing leads to high 
mechanical forces neutralizing the low BMD efii:ct of 
a thin body type; bone accretion may be enhanced by 
weight-bearing exercise, allowing some amenorrheic 
athletes (i.e., tennis players, ice skaters, runners, 
gymnasts) to have normal or increased HMD. 
1!1.anagement of polycystic ovarian syndrome 
Polycystic ovarian syndrorne (PCOS) is 
characterized by hyperandrogenism and chronic 
ol!go-ovu!at[o;; ( P). The clinical presentatiml is 
heterogenous and often difficult to recngrtizc irt 
adolescents due to the coinciding signs and symptoms 
of pubt.:rty including lncreased androgen production . 
Table 3 provides key features of PCOS as well as a 
differentia[ diagnosis and suggested laboratory 
evaluation. Table 7 )i$ts laboratory results which may 
be found in PCOS and support the diagnosis. T<.tbk 8 
Ests potentia] management options for adoh::scent 
females with PCOS. Trea~ment of PCOS ls 
multifactorial and includes addressing obesity if 
pres~mt, thxreasing androgen )(.;vels, an.d improving 
insulin resistance. Or<i.l contraceptives (OCP's) are the 
mainstay of treatment in PCOS. OCP' s decre-ase Ui 
secretion and 'thus decrease ovanan androgen 
secretion, protect the endometrium from unopposed 
estrogen :;tirnulation, and increast: sex hormone 
binding globulin •vhich then decreases free 
testosterone to improve hirsutism and acne. No 
specific OCP has shown to be more effective; 
hnwevcL Yasmin vvhich contains both ethinyl 
estradiol and drosperinone decreases both ovarian and 
adrenal androgen secretion. Medroxyprogesterone 
{Provera-·····1 0 mg) or micronized progesterone 
(Prometril\m) can. also be prescribed to induce 
withdrawal bleeding if this is taken orall.Y for 12~ 14 
days each month. 
~-Iypcrinsulinemia (f::tsting levels of glucose/insulin ratio <4.5) 
'1 H M''d t ~J : t. !l .. I 
[FSH: Low limits ofnorm:al 
~JH-.FSH ratio: > 2.5:1 
[Estrodioi: ~vfoderate t 
ll7-hydruxyprogcstcrone: mi1d f 
Androgen: mUd to moderat~ j in levels 
-free and total testosterone 
-early morning urinary 17 -ketosteroicls 
-androstenedkmc 
-dehyd.roepiandrostt~rone sulfate (DBEAS) {;,;an also be normal) 
Sex hormone-binding globulin (S1-IBG): ~ 
· rolactin: Mild t 
Abnonnallipid protlle 
·l high-density lipoptot<;)in. 
-t cholesterol 
! 
- ; very-low density lipoprotein 
:,, 
- r icv;-dcnsity lipopi\}[e[n 
L .......... ~ .. J ... ~£~·~!>.:?.~~~9.~.~------· .. ···· .. ·························"· .. ---~----------------------...J 
~ ~ . : . : : : . : . : : : : . : . : : : . : 
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Combined Dral contraceptives 
Transdcnnal (patch) comraceptior: 
Transvaginal hormonal con!racepti vcs (Nuva R!ng) 
f'ro gesterone 
Spironolactone (andr>Jgen receptor antagonist) (hirsutism) 
Flutm.nide (androgen receptor antagonist) (hirsutism) 
Metfom1in 
Management of obesity 
Management of acne vulgaris 
Hair removal (Electrolysis and Thermolysis) 
Ovulation induclion (usuaHy <m1y for adults) 
• Oomiphene citrate 
- GnRH agonistic analogs (Ieuprolide acetate or na13relin} 
Laser ''driHing" of the ovary U ovarian stromal steroids by reduci_ng the stroma:) 
Managem{~nt of potential co-morbid ~:ndocrinopathies 
The treatment of hirsut\sm can include shaving, 
bleaching, d<;pJlatories and c1cctro1ysis. 
Phc=trmacobgic treatment indudes et1ornithine 
{Vanlqua) \Vhich is an approved topical cream that 
acts as a hair growth retardant. 
Androgen receptor antagonists (such as 
spironolactone [50 to 100 mg nvice a day]) or 
antiandrogens (such as flutarnide or cyproterom~ 
a(.;etak), though not approved tor the treatment of 
hirsutism, are commonly lJSed. J\:ietform.in 
(Ghwophage) can be used to Jowcr sen.:m insulin 
levels along --.vith reducing ova.rian cytochrome 
P450c17a activity and hnproviHg byperandrogeu.ism 
found in obese PCOS adolescent females 
Early intervention with androgen suppression 
therapy :a1ong Vlith exercise and proper nutrition can 
improve th~ lives of these youth in their future 
adulthood. It is also important to address comorbid 
condit](.JDS including depression and other mental 
health conc~rris. Future complications of ado1escents 
with PCOS include the potential of er:dorrwtr1al 
carcinoma, diabetes mellitus (type 2), infertility, 
cardiovascular disease, and hyperlipidemia. 
Dv4unctiona1 uterine bleedin;;: 
~- ' -
Excessive, sust.-'1incd, or uhpatterned uterine b1ecdlng 
not caused by anatomical lesions defines 
dysfunctional uterine bleeding (DOB). It is QHe of the 
most common mcnstnv.1l concerns of adolescent 
females and is noted in about 15% of all females 
seeking gynecologic co;lsultation. DUB may l;-)ad to 
anemia (ranging from mild tc severe), absence from 
school (or \vork}, spontaneous muscle or joint 
bleeding, or posHurgicoJ bleeding. 
Table:; 3 and 9 provide a list of DUB etiologies 
that include a.novtda.t!on, compl icatinns of pregnancy, 
anomalies of the reproductive tract, disorders of 
coagulalhm, ttmlm<l, endocrinopathies, other systemic 
disorders, infection (such as pel vic inHammatory 
disease or PJD), and others (4). Table 3 provides 
suggested laboratory tests that may be oht.ained in the 
eva.hJation of DUB. 
DUB management 
Treatment of dy·sfunctional uterine bleeding consists 
of treating the symptoms associated, as wdl as the 
cause. 
·rhe ilrst step, next to identifying the cause, is 
diagnosing the level of anemia, which is based on the 
classification of mild anemia (hernawcrit over 33% or 
hemoglobin over l 1 g/dl), moderate aneuua 
(hematocrit 27 to 33% or hemoglobin 9 to 11 g/dl), or 
severe anemia (hematocrit under 27% or hemoglobin 
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Table 9. Cause~ of Abnormal Vaginal Bkeding~k 
365 
--------············-··············--·- ------~---------------------------·----------------~--~-------------------------------------------------------------------
Ex dude Tectal, urethral, and other perineal bleeding 
Vaginal or uterine abnormalities 
Trauma {coitus, rape, abuse) 
Foreign body (H.JD, t-unpou, etc) 
Infection 
Tumor 
Vagbitis (trichomonas, gononhea) 
Cervicitis 
Endometritis (tuberculosis) 
Pelvic inflammatory disease 
Sewally t-raJ.1~mitteJ co11dylomata (HPV) of cc~rvix or vagina 
Botryoid sarcoma 
Polyps (uterine, c~rviea1) 
Ovarian eys;: or tumor (mature teratnma, endometrioma) 
!A:'i omyom atos i:; 
Clear cell c:arcnwma of cervix or vagina (DES) 
Other ovarian malignancy and metastatic malignancy 
Endometriosis 
Conget:.ital malfvrmations of uterus 
Complications ofpregmmq 






Thrombocytopenia (idiopathic thrombocytopenie pmpma; leukemia; !ymp!mma; aplastic anemia, 
hypersp!cnism) 
Platelet dysfimction (von Vv'il lebrand' s disease; G lan7mann '~ disease) 
Clolting disorders (hcmophiEa; other coagc1!ation factor deficiencies) 
Uterine production of memtmal anticoagulants 
DysjiJnctional uterine bleeding 
Nonna1 Vatlatkn 
Midcyde ovullltmy bleeding 
Early postmenarchea1 anovulation 




Miclcyclc breakthmL~gh bleeding 
Relative luteal progesterone deficiency 






.. · ... ;·:· 
. : :: =·~ 
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Table 9. {Continued) 
--~····-................. _______ ........ ~.~----~------




Natural h()tmones from plaJlt extracts (DH.EA, Dong Quai, Yam Extract) 
Systemic diseases 




Chronic Ewr disease 
Croh.n's disease; ulc<~rative colitis 
Chronic rcnat disease 




Exogenous androgens, PCOS., congenital adrenal hyperplasia& 
Androgen-producing ovarian or adrenal tu:m.or 
Est1·ogen excess 




Physical stress, especially exercise 
Ovulatory 
Short htteal phase 
Prolonged luteal phas~ (Halban 's di ~case) 
Luteal progesterone insufficiency 
............................... ,.... ._ .............................. ................. ___ _ 
Abbr~;viations: HID '" llltrauterine device: HPV "'-' human papillcmav·i;;is; .......................................... _____ .................. . 
DES: d1ethylstilbtWtro1. 
·~Keprir.ted, ·~vith p{!r;ni s~ian, ii:om: Gr~y,ianus DE: Breast and GynccologicaJ Db on:l.ers. In: Adolescent Medicine, 3'J 
Edition. Eds: r\D Hofmann and DE Gteydanus. Stamford; CT: A.ppieton and Lang. 
Absence of anemia or mild anf:'mia 
Reassurance and monitoring over timt: is often all that 
is needed for mild DUB with no ()r mild anemia. The 
patient can be instructed to carefully Iollow ner 
menslmrtl cycle-s with a menstrual calendar that can 
be presented at office '\>i sits for review by he:r 
clinician. lf mild anemia is present evaluate dietar:,-' 
inatke arid suppkment \Vith 300 mg of ferrous sulfate 
three tittles a day. Table 10 outlines potential adverse 
effec:rs frorn iron supplementation. A slow release 
fommlation can decrease some side effects . 
Constipation is a coml'non side effect and thetcfore~ a 
stoo l so tt<::ner is often started when i ron is 
supplemented·. Vitamin C is often also adde(l to each 
dose of ferrous sulfate lo enhane:e absorption. 
Tabie Hl. Adverse Effect§ o:Unw. S1appkme:ntation 









Constipatiori (add stool softener to prevent) 
Dia11'hca· 
Stools tb~t are bia~k 
Discoloration of urine 
\Vorsening ulcers/colitis 
Adolescentfemale menStntal disorders 367 
In addition to treaLi.n.g the anemra, combined om'i 
c:ontracq:>tives (also, patch or nuvating) can be used to 
help reguh1te n:;.enses and help avoid unwmtted 
pregnancy, Depo~medroxy-progesteronc acetate 
(DMPA) is not typically recommended us it may 
\Vorsen the menstrual inegularity and potentially lead 
to amenorrhea; an intramuscular ii;jection should be 
avoided in those with coagulation disorders. NSAlDs 
(non-steroidal anti-inflammatory drugs) are helpful in 
reducing menstrual blood t1o>v by as nwch as 50% via 
a din~ct effect on lhe ondometl"ium that balances the 
vasodilator prostaglandin. I2 and the potent 
vasoconstrictor thrornboxane A2 (17· 1 9). 
I'vioderate anemia 
Combim~d oral cotltrac.eptivcs (typically a. 30 tQ 35 
meg ethinyl estrodiol type) <tre used to control 
bleeding in patients with DUB marked by moderate 
anemia. The importance~ of estrogen is that it binds to 
receptors in the endometrium, provides stabilization 
t>f the endm:',ctrial vasculan.trc and stroma, and 
stimulates specific growth factors, 
The pill can be provided 2 to 4 times a day i.mtii 
the bleeding has stopped and then gradually taper~d 
ever 14 ro 21 days to aHow :for withdrawal bleeding. 
It can be contbued <~t a onte a day dosage for the next 
few month!'. or ltJnger if m~cessa.ry, A longer dosing 
pattern {3-6 months) will atsc• aHow com~ction of the 
underlying <.memia. 
Higher levels of estrq;en may cause nausea and 
therefore, an anti~cmctic m~dicat~on can be added to 
alleviate any nausea or emesis that may occur. Iron 
supplementation can be provided as discussed 
pr ~viously. 
Ati alternative to use of an oral c(mtraceptive is 
prescription of or:~l equine estrogen (2-5 rng f()t 21 ~25 
days each month) followed by lr,edroxyprogestone 
acetate (HI mg a day) for the last 7 days of the 
menstrual cycie. The use of prog~sterone-on1y agents 
is preferred by some clinicians, as outlined in Table 
11. Initially. high doses may be needed to induce 
endometrial atrophy and then estrogen can be 
continued for a number of days to avoid break· 
through bleeding. 
Some physicians add an ond progesterone <'.gent 
over the last 1 0 days of the menstrual cycle each 
month to avoid ,_mopposed. estrogen effects, aHm.v 
endometrial stabilization <Jj1d allo~' organi1.cd 
endometria\ sloughing. Concerns about using cyclic 
oral progestin therapy include potential bloating, acne 
vulgaris, increased appetite-induced weight gain, and 
reduced contracept1ve effect. 
TaMe 11. DUB C<:n:~lrol with Prngcstcnmc--msly Agent~* 
lA. Mcdroxy-pwg~-:steranr. ;:u:etatc (MPA) l. 10 mg q4 hours. then QlD-4 days, TID-3 days, BUJ-14 day) 2. high dose may be necessary: 40-lW mg per day or 1 OQ mg Depo TM/d.av t . . -i B. Norethindrone acetate 
! l. 10 mg q 4 hours. then q6·8 b"s to 12 hours; taper as bleeding decreases 
j 2. May stay on 5 mg q 12 hrs for months if necessary with i if necessary (as teen \Vith aplastic anemia an 
i 
i lo:.v platelet <:ount) 
i i 3. 0.35 mg OD------BID for brcaklhrough bleeding 
j C:. Megestrol acetate (SO mg HID may be needed) 
~----·---·--·--·-·-·------ -·-............................. .:...------------------..,.,.----------' 
''-Moddii:d v-:lth permis:;ion from: Greydamw DE, Omar HA, Tsitslka .AK, Patel DR: Menstn1at d.i~nrdcrs in adolescent 
females: Curteot concepts. Di.s-A-Momh 2009; 55(2): page 60. 
Severe anemia 
Intravenous :fluids and blood products may be 
necessary in this situation along with high dose 
estrogen, such as usc of intravenous conjugated 
equine estrogens (25 mg initially 2 .. nd repeat dose 
ev~ry4·6 how-s for up to 4 doses) ( 4, 17-19). 
The high dose estrogen. induces rapid hemostasis 
because nf increased production of fibrinogen. 
i!1creased activity of Factors V and IX, and incrcast~d 
aggregation M platelets. Use of such high dose 
estrogen may increase thromocmbotlsm risks. 
An anti-emetic, again, is added to control the 
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a.dded to indm:e controlied withdrawal bleeding from 
the endometrium. Some clincians prefer 10 use <>n orai 
contraceptive dosing pattem (see Table 12) to avoid 
use of intravenouii estrogen. 
Table 12. O.rat Contrat~;ptive Sd teduie to Control Severe DSJH* 
.---------····-, ·---··············- - -··-····---- ------------iL l)tilize a monopha:;ic combination OC with at l~ast 35 mog ~thinyl estradiol 
Fcur limes u day (with art a.toti .. etneti,:) umil the bleeding stops 
Three t!mcs a day for 4 days 
Twice a day for two to 1hree weeks 
Allow a wntroHed withdrawal bleed 
Start the oral contraceplive and. oral ·iron supplements at once a day for 3 to 6 months 
"'Mcdin·~·;rwith pe;·missi~~-·from: Greydam1s DE. Oma.r HA, ·i.~its.ik~ AK, Patel DR: Mens.tr:..!l:!l· ~-ii~~rders in ade!csccnt 
femal es: C:ment concept". Dis .. A-M:onth 2009; 55(2): page 60. 
Table 13. Effecb and »cn~ilt.s of LcvoiWrgestrel HJn·.-
r··--------·-----····•••o.'".. -------·--·-••o.• .... u••--~~-........... l Gmtrapeptive Ef{t.•cts ~----·--··············-·-----------···············-·----,~--.., 
: •Prevents fertilization 
: i •irtlerferes with ovurn development 
! • Interferes with sperm mowmcnt and ability to penetrate ovum l •.Inhibit.> spen-::1 survival 
•Helps prevent egg release 
•Thickens -cervical mucus 
Benefits 
•Etiective contraception for 5 years 
• E~·cntuai reductioP. in meJ1stnla1 f1 cn·Y 
·OK for those with coagulation disorders 
•Up to a 90% reduction in bleeding 
•20%-50% with no menses after one year 
•Good for those with Mc.T:.taJ retardation/Developmental Disorders 
•Fr~quentamenor.::hea 
• Decreased dysn::.mon·bea 
•Decrea~ed. premenstrual syndrnmli 
o Very lo::_~·ates of infectious complicnti~E:~ ......... _____ ······---·--·-· 
*Modified with pe.rmi&sicm from: Grt~ydanus DE, Omar HA, Tsit'>ika AK Patel DR: Menstrual disorder·s in adoiestent 
females: Current concepts. Di:H\-Mon.th 2009; 55(2): psge 64. 
Management of DUB due to coagulation 
disorders 
Control of DU.f> in adolescent females with 
coagulatipt1 disorders can be complex and 
consu:ltation with experts in hematology 1s 
recommended ( 4). The cornerstone of bleeding 
con:trol is appropriate factor replacement therapy with 
additional pharmacologic agcmts that include 
intranasal DDJ\ VP (1-deatnino-8-D-arginine 
vasopressin) (Dcsmopresslri acetate), antifibrlnolytks 
(cpsilnnamino caproic acid (Amicar] or tranexamic.: 
acid (Cyklokapron), combined ora! contraceptives, 
and/or levonorgestrel-releaslng IUD (~Hrena). 
Co.mbined or~J contrac~ptives ra.isc Factor VIE 
activity (FVHl:Ac) in hemophilia catTiers. In patients 
with von "\V illebrand' s dis east;, estrogen raises factor 
VJnlvWF-ristocetin cofa.ctor activity, and partially 
corre-cts pr9longed bleeding time. If there is a history 
of deep vein thr(lmbosis, and estrogen is used io 
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Other D[IB anage.rnent option.~ 
There are other tre<'.tment options comr:nonly usf.1d in 
adults, but less commonly in adolescents "'rith severe 
aod/or persistent DUB. These potentia1 management 
stratcgi~s include da.nocrine. GnRH agonists, and 
surgical options, such as dihtiion <tnd curettage, and 
hysterectomy. Danaznl (D~mccdne) is a svnthct[c 
hormonal agent prescribed to manage endometriosis, 
breast cysts, and S{cvere DiJB in adult females. Its 
benetlts includes estrogen suppression and cessRtion 
of mcnstruatil)n {4} GnRh agonists (Le. buserelin , 
leuprolidc !Lupi\m Dcpo 1, and nafarclin fSynarel]) 
stop menstruation, but there is Emited research data 
on their use in adolescent fcmaks. 
Dys.meno.r.rhea 
Dysmenorrhea !S typica.Jly divided into pri:mary and 
secondary dysmenorrhea. Prirmuy dysmenorrhea 
refer~ to menstmal pa.irJ with no underlying pelvic 
pathology; secondar)' d)lsmenorrhea refers to pdvic 
(menstrua)) p<'!in resubng from anatm:nic and/or 
pelvic pathology. Table J outlines the definition and 
differential diagnosis tor dysmenorrhea. 
Primary dysmcrHwrhea is often classified as mild, 
moderate, Gr severe. Mild dysmenorrhea does not 
interfere with normal daily activities and only 
minimal analgesic support is needed. \Vith moderate 
dysmenonhca, there is some reduction in activities 
<md the use of analgc:>ics is rccessary. 
Severe dysmenorrhea imphes that regular 
activitie~ do not occur during the active phase of the 
symptoms and ana1gesir;s are usually not beneficial. 
Approximatdy tw()·thirds of ovulating fermdes report 
some menstrual discomfort for one to three day~ of 
tn(ISt ovulatory cycles wlth about ha)f having mild 
dysmenorrhea, one--third with moderate cta.'11ping,. and 
ahnt1t 14% with severe dysmenorrhea (4-). 
Primary' dysmenotT.hea i~ the most common 
medical reason for school or work absence and it has 
an increasing incidence from the early adolescent 
years to young adn1thood and first pregnancy (20,21 ). 
Primaxy dysmeno:rrhc8> often sta;rts 6 to 12 months 
post-menarche, though it may not been seen until the 
third year pnst--mena,n:ht.\ 
The pmn associated \Vlth menstruation may start 
before the initiation of menstrual flow or once 
menstrual flo"v starts. The symptoms associated with 
dysmenorrhea cun vary pc.thmt to patient and are 
illustrated in Tah!e 14. \.Vhen a patient presents with 
dyr;mcn(Jrrhea, the first litep is to differentiate prirnary 
lrom secondary dysmenorrhea (see Table 3), It is also 
helpf\1! to identify factors wb ich can allevi<:1.te or 
aggravate the paln (T<1ble 15). 
Etiology 
The etiology of the menstrual cramping ln primc.ry 
dysmenorrhea is due to the condition:;; set after 
ovHlation occurs with the increase and decrease in 
progesterone levels that indur;e release of 
prostaglandins that stimulate a rise in uterine 
contracticm.s a:.1d endometrial nerve endings' irritation 
(21 ).3 ). The result is variabJc menstrual cramping and 
pain due to a rise in myometrial rcst~ng tone, 
increased frequency and amplitude of c<:mtractions, 
and a rise in dysrhythmic contractions. 
Those wlth primary dysmenorrheu have higher 
levels of circulating prostaglandins during 
menstruation in contrast to those without sv.ch 
cra..<nping. h' addition, research suggests that those 
with primary dysmenorrhea have heightened 
sensitivity to prostaglandins in the circulation and also 
higher vasopr~~ssin levels that can lead to increased 
uterine contractions and increased menstrual pain. 
Tabie 14. 1-'e».l-ures Assoda.ted 








Low abdominal pain 
Headache · 
Inner thigh pain 
Dianbea 
l .ightheadness (dizziness; flushing) 
Di:-':ziness · 
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Primary dysmenorrhea management 
NSA..liJs 
'fhc initial pha.t--:rna<.:ologic management for thos(; with 
primary dysmenorrhea is non--steroidal anti-
inflammatory drugs (NSA TDs) that includes non· 
sckctive (COX-1 and COX--2 inhibitors) (Table 16} 
an.d selective or COX~2 Inhibitors. Efficacy in the 
management of primary dysmenorrhea includes th~.: 
suppression of cyclic endoperox:ide synthetase at the 
cyclooxygenase leveL In general, there is often no 
difference in efficacy and choice of therapeutic agents 
is determined by cost, cmyvcnicnce, adverse effects, 
and patient preference. Jt is thought ihat eno1ic acids 
(i.e., oxicams) may not on1y be not as effective ft;r 
p1·imary dysmenorrhea, but also have many more side 
effects. 
The NSAIDs with the highest benefit with iO\vcst 
adverse effects are the ptopionic acids: ibuprofen, 
naproxen, naptoxen sodium, and keroprofen (Tables 
16 and 17). Propionic acids are FDA approved tor the 
treatment of prirna.ry dysmenorrhea and dosages are 
listed in table 17. Side effects include headache, 
gastTointcstlna1 up.sct, bcattbmn, indigestion, rash, 
and dizziness. Naproxen sodium has a long half-lik~ 
allowing for twkc-a~day dosing. Ketoprofen has anti .. 
hmdykinin action, provides stabilization of lyosomal 
nl(;tnbranes, and Inhibits prostaglandin as wen as 
]eukotriene synthesis. 
Several propionic acids ate available as ovcHheN 
cotmtcr agent~; and highm do~es are available with 
prescription. As discussed previously, it is helpful for 
the patient to keep a ca.lendar of her menstrual cycles 
so that she kno>vs when her menses shouid start and 
can initiate pharmacologlc therapy. lvtedication can be 
continued for tv:o to fou•· Jays as needed for pain and 
reduction of blood 1oss. Partial to near cornp1ete pain 
improvement is noted in about 80% of those w!th 
primary dysmenorrhea. Failure of bencfH mt:.y be due 
to absence of prostaglandin &y·athetase inhiblwrs 
blocking the 5-lipooxygenase pathway that allow·s 
continued production of leukotriencs. H is also 
ii-!1pcrtant to rt~member that if there l!i llO 
improvement in pain, secondary dysmenorrhea shodd 
be considered. 
Table 16. NSAIDs: Noia--Sc.!ectiv2 
(COX--1. and COX-2 I11.hibtto~s) 
·····························-·---:--:-----:-:-~-~-
!. Salicylic acid estr,rs: aspirin 
2. Acetic acids: indmndhadn, ; sufindac, ! 
tolmetin, nahumcton~ ! 
3. Propionic acids: ibuprofen, naproxen, 
1 naproxen sodium, ketoprofen, f1mbiprnfcn i 4. Fena:rnic acids:mefenru:nic add, I medofenamat~~ 
~~~-~5 __ ~:~~-d": pii"oxican:t 
Used 1-vith perimissicm from: Greydanus De, Omar HA, 
Tsitsika !\K. Patel DR: "!Yienstnml disorders in 
adolescent females" In: Pediatric and Adolescent 
Sex;;aiity and Gynecology: Principles for the Primary 
Care Clinlcii.'v~. NY: Nova Science Pub1ishers, Inc. ch. 
7: 386, 20 JO. 
Salicylic acid esters (i.e., aspirin) are not 
efficacious in t:reatrnent of dysmenorrhea as it has 
limited anti-inflammatory eff~cts on the 
endometriiltn. Indomethacin is an effective agent but 
has significant potentia! ~ide eO(oc~s inch!ding renal 
insufficiency, prolonged vaginal bleectlng, headaches, 
gastrolntcstinal ulcers and gastric blcl.:ding. Fenamic 
adds (tncfen(l.mic acid lTable 17), medofenamat;)) 
have a rapid onset of action and can reduce b1eeding 
in patients with menotthagia, These medications act 
by h1ocking myometrlal receptor sites for synthesized 
prostag1an"<1lns as well as lead to inhibition of 5-
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i Dmg InitC.aCDose·-························-~·-··Maintenaiic~ ........ ___ ! Maxiwum Dose/ 1 
i (mg) D()~e 1 24 hours (mg) i 
L ... _........ -·-.. -·-·-·-·---l-----·-·-····· .......................... 1.. .......................... :.: .................................... ) I !!:mprofer.• 400 J 400 mg q4h j 3200 f 
I i I 
I i 
I i KeloJ.mifen 25--50 1 25-50 mg q6-8h 1 300 
I l Naproxen~ sodium 55D 1 275mg q6-Sh or 550tngj 1375 
I i I q12h ; 
I i 
I i 
Naprox.cn 500 I i 
250m.g qfi..8h or 5(}(}m~ 1250 
5DO q!Zh i 
. 25'0 mg.q4h l, Not ''s•ablJ"she<! . , Mefenamic add ~-  
·:A:~;a-ua'bie·~·;,--;;·v-e-r·-~ii1e".:coi~~;_te-r drugs in u.s.: ;buprofcn; 2oo-mg tablets; rtaproxe;;·~;dl·;;;n:~-~~2-o~·n:;·g·;:ai)i.eii ................................. , 
*Used with pcr.imissicn from: Greydanil.s DE, Omar HA, Tsilsika t\K , l'atcl DR~ "Menstrual disorders in adolescent 
females'' Tn: Pediatr:ic and Adolescent Sexuality and Gynecology : Principles fnr the Primary Care Clinician. NY: Nova 
SciencePub!ishers, Inc. ch. 7: 3R7, 20W. 
Tah!e 18, ~bnagemeut Optio11S for Primary Dysmen(lnhea 
....---···---·····----·--······---~--··-······························-·-
' SAUJs (Tables lo and i'!) 
:onnona! Contral:eption {FiU, patch, i.ratHvaginaL i),\jectuble, imphmt;;blt:) 
0s~ a m~n!;truai Cl~lt:mh1r (to ir..kntif'; men;;truai pattern) 
Ensure adeq~t<\te· rtJ;;t,. sl~p, ;:.nd ex-.n.~isc 
~cquct!on of psydtologica! factors (as de-pression, a...xicty, excess ~'tress) 
ish consumption (omcga-6-fatty acids)? 
eduction of caffeine and sugar 
Unproven :mt:thods 
Calcium channel blockers (i.e., nifcdipine ·· ·tried in adult patients; c;;rt l.eoii te hewl~.ches, hypotension) 
AcupunctDre 
Transcutaneous elcctr~cal nerve stimulation (TENS). 
Oral contraceptives 
Combine\1 oral contraceptives (COCs) may he u~ed 
for prilr1<liY dysn1enorrhea. if NSAIDS are not 
lx~ne±kial, as adjunctive management to NSAfl)s, an.<.l 
also as first line therapy lf the patient is Sf.lekmg 
contraception. COCs prevent ovulation and b!ock the 
development of the post-ovulatory fist~ in 
_prostaglandin levels because of the ovulation-induced 
corpus luteum. Blood flow is often reduced an.d 
m.cn.stt1Ja1 cnmrp~ are ks/;ened ir: up to 95% of 
females with primary dysmenorrhea on COCs. Other 
.forms of hormonal contraception ::-..:re also eff-icacious, 
such as the. patch, t·ansvaginal, injectable,. or 
implantabie (subdermal) methods, If a combina~io.n of 
NSAIDs ~~d hormonal contraceptives are not .helpftl.l 
to a considerable extent, con&idcr that the patient may 
have secondary versus primary dysmenorrhea (see 
Tabk 3 ). Other .management options fi)r trr-atment of 
primar.f dysmenorrhea are listed in Tabi!! l.8. 
.S'econdary dysmenorrhea 
There arc many diagnoses in the d!ffel~cntii.tl for 
secondary dysmenorrhea including endometriosis, 
pelvic inflatnn1atory disease~ reproducthlc tract: 
anomaiies (Mullerian defects), and other~ (see Table 
3). A careful rnedical history can often provide clnes 
that an organi(: lesion is the cause of the 
dysmenorrhea. For example, the pain may hegirt at 
menarche or thr~c years {or mort:) atler the onset of 
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menses, There may he atypical pain, pain associated 
with DUB or c:hanging menstrual patterns. pain that is 
not relieved ·with NSAlDS m1d horrni\nh1 
contrac$ptlon) anJ pain that devG1ops after 
surgery. 
' ' peiYlC 
Table l9. Medlc:~l Hi~tury h1. a Patient with Dysmenorrhea* 
f/\-g-e·;t:·~;~~;;~~~t~~-----------------------·---·--·-·----·--··--··- --------·-···--·-----------------------------, 
i Last time mcnstruatbi1 w~-re regulm: (if <:1 a!l) 








Severity orthe pain: mild, moderate, severe (arc activities di;,:rupkd?) 
Do pain medic~tions improve c~r reHcvc the pain? 
Flow description (dura.tion ~md qutmtity) 
Association with systemic far.;.;ors 
Sexual h~stmy and usc of any con1.rw.:epti!Jn 
History uf pregnam;y (and its outcome-) 
History ur sexually transmitted infecti<ms 
Hi~tory Qf dyspa.reunia 
l fL~tory ot' other systemic disorder<> (i.;;;., g<lStrointest:na!, genitomr:nary, oth<=r~) 
History of surgical procedures 
Fan:ily history of various gyne<•ologic conditions (dysmcnmThca, endom~triosis, ovarian ~~y~ls, infertility, virilization, 
cnncer, u~h~rs) 
•••••~·-•-••••••·--------~---•••-••~•••••·~···H·HO. ...... O........._..._._.. .............. ~ •• -•••~••••-••••-••••-••••-•••••••••••••••••• ........... ._ .. ~--· ..... u•••••••••••••-••~•••••••••••••-••~••••••••••• ...... .... 
*Used with pc.rimisslon fwm: Greyda.rws De, Om;lr H .. '\, Tsitsika AK, Patel DR: "l'v1enstrual dismders in adolc.si:ent 
females'" ln: Pediatric and Adolescent Sexuality and Gynecology: Principle!; for the Primary Cam Clinician. N"Y: Nt•Vfl 
Science Publishers, lm:. ch. 7; 384, 2010. 
Table 19 outEnes questions to a.o;;k in the medical 
history to help delineate between primary and 
secondary dysrnenorrhea. !-\ carctuJ examination and 
selective laboratory testing are ne(~essary to identify 
the underlying cause (Table 3 ). Management is 
dependent on the underlying etiokigy (4). 
Endomctr!osi~ is one of the most common causes of 
secondary dysmenotThea. 
F.:miom etriosis 
The development of endometrial ~troma and glands 
outside of the uterus ddines the core feature of 
endometTiosis. Thoc1gh more cornmonly associated 
with mhiH females, it may been seen in half or more 
of adolesc:ent females 'Nith chronic pelvic pain. 
RefJu..-x of endornetria[ tissue from oviducts during 
menses may occur in a process termed retrograde 
menstruation; other mechanisms include the 
d(;velopment of endometrial tissue from sri1ail cysts 
found over the pelvis, such as uterine surface, ovaries, 
pelvic ligaments, or the peritoneum (coelomic 
tnetaplasia). 
The precise underlying mechanisms are unclear, 
and thus various theories are proposed to explain why 
B Blllliilllllllllllllllltt 1 Ill 1tll E EIIIIIJIIJIE I 
endometrial tissues are not cleared from non-uterine 
locations; these theori(~S include immunologic 
defkicndcs, !ymphatic--vascular meta::.tases~ and 
genetic factors. Re\;cnt research f(x;uses on the major 
role of prostaglandin E2 (24). Pain arises in 
endometriosis because of swelling (lf endometrial 
cysts during menses, pelvic adhesion-indl.J,ced pain, or 
stimnlation of various pelvic nerve endings, 
S-ymptomatology 
Features consistent with endometriosis inc.!ude severe 
_d.ysmenorThea tmrespunsiVi) to analgesics or hormonal 
medication, chronic pelvi~~ pain, and inkrtility. A 
vari~~ty of pain pattc:ns exist d(!pending on the 
location of the endometric)tic 1esiom. There i~ no 
association between the mtrnbcr of lesions and the 
pain intensity. Abnormal menstrual bleeding can be 
seen aJong -..vitl1 various other symptoms, including 
clinical hematuria, suprapubic pain, dyspareunia, 
andhr dysuria. Variable gastrointestinal 
syxnptomatology may also be present and include pain 
v;ith defecation (dyschezia), rectal pressure, and 
urgency. Endometriosis can als<,; present with large 
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-------r-------·-------·--------------·-·---------------------------- -·-----------------------------------·--·---------------------------------·-------
Characteristics of Pain Likely DiagnDsis Confin:natory Investigations 
:--------------+----· ------+----------------·-··--·---·--·-·······--------l 
• MIDLINE LOCATION 
Cydic<tl,nonnal bleeding 
Physio1cgic:a1 dysmenonhea History; pelvic exi'Jninatim; (normal) 
Endometriosis 
Endometritis 
Acute, irregular bl.eeding 
Pelvicexarninatio::.; smwgraphy; 
laparoscopy 
Pelvic examination, cultures; CBC; 
sediment<Jtion rate 
Threatenx or septic 
abortion 
History; p~lvic examination; pregnancy 
test 
Cystitis Histery; urinalysis, urine culhlH~ 
l]melated to menses, 
~Jtinary sy.m.ptoms3 Normal uterine pregnanGy History; pregnancy test 
• LA.TERA L LOCATION 




History (Liming, nature); pelvic 
examination (nonnal) 
Pelvic examination; ~,or:.ography; 
laparoscopy 
Acute, a.bnonnal bleeding 
Salpli1grtis or pelvic 
i.nf1mmnatory disease 
History; peh.-ic examination, cl!ltures; 
C.BC, sed rate; laparoscopy 
Unrelated to menses, acu~e 




Ureteral co lie 
Constipation 
!::listmy; pelvic examination, pregnancy 
te&t 
History; physical examination; CBC, 
radiography 
.History; tui.."'laly:i!s; radiography l 
~ 
Pelvic osteomyelitis 
Hi:;tmy; rectal ex.arni.uation J 
P. 1. 1ysi. c:::.·l exa-mination. : rad.iog:raphy; 
gallium scan 
Psychogenic Histoly; exclusion of others; 
psychosocial evaluation ·-~· 
Abbreviation: CBC" complete blond count. 
''Dysuria and urinary freqv<;ncy may he a~sqciated with infection. pn~gnancy, and psychogenic factors. 
Reprinted, with permi~~ion, irom: Greydanu.s DE: Breast and Gyneeologicai Disorders. In: Adolescent Mdicine, 3'd Ld;tion. 
Eds: AD Ho1:'1Ja:m and DE Greyda.nus. Stamford, CT: A~;plet.on and Lange, ch. 25: page 5117, 1997. 
Diagnosis 
Identifying the pattern and loca.titm of pain can help in 
differentiating the etiology. Table 20 Qut!ines a 
diagnostic approach to adolescent females V.'ith pelvic 
pain. Table 21 outlines a diagnostic -pian for pelvk: 
masses. A pelvic examination m a patient with 
endometriosis may be normal or reveal various 
abnorma!ilics, such as pelvic tcndBmess, Hxed 
(immobile) uterine, thickened broad ligaments, and/or 
unpredictable nodula:rh)' with or without tendemess. 
Various pelvic c-ysts or an adnexal mass may be noted 
by ultra.sonography while a pelvic l\tRI may reveal 
genital reproductive tract anomalies, Females with 
endometTiosis may have an increascG CA~125 (c(~ll 
surface antigen). AJthongh this test has a low 
scrtsitivity and is not a costcefficient screening test, 
levels of this antigen can be used to fo1lo-.v ~linical 
response to trca.tment. The go~d standard of 
diagnosing endometriosis is laparoscopy with biopsy 
and this should be perfonncd in adolescent females 
with chronic pelvic pain of unlmown cause not 
responding to NSATDs and hormonai medicati-on. 
Endometriotk lesions can appear dit"fereutly m 
adolescent versus adult females (4) 
~ : . . . . . . . . : . . . : . : . : . : . : . : : 
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Table 2:1. Diffenmtlal Uiagnosis ofPeh:ir :\1ass~s 
r~·.···-----------------·---...... -------------~--------... ----·---·----------·------~----·-··-·····~· .... ! Characteristic of Mass Ditlen:ntiat Diagnosis 
! 
( ....... ---,.......................... . ........................ --------! 
i ~MIDLINE LOCATION Pregnancy 
Confirrnatory History, 
Findings, and Procedure 
i:rT~·[;;~: Gf sexual (lCtiviiy~'"p(;siti:Ye"i}e'i~:;c-·----~-
I With a.tn~norrhea or 
1 abr1onnal1n~nscs Hematocnlpm, 
hematometra 
Utcrin.e sarcoma (rare) 
Bladder 
FuJlctioning ovariar1. 
cyst (Table 3) 
Ovarian tun1or 
Polycystic ovary 









Danazol, a steroidal androgen can be used which 
suppresses cyclic clmnges and eventually causes 
atrophy of the endomett~otic sites, Carefu! 
observation of potential adverse effects is Important 
and th~:se rnay include including fetal 
androgei1isation, thrombotic ~vents, elevated liver 
function tests, hyperlipidemia, acne vulgaris, weight 
gain, edema, and others. 
examination 
l-h~tory of nc. tnenses, ryc.tic pelvic pain; 
perineal examination reveals imperforate 
hyn"'l_c_n_: vagina_~ st,~no3)s 
N~gative pregnancy test; uterine enlargement; 
sonography CT; tissue diagnosis 
History of a.~:nte :reknL~on; findings of herpetic 
or other lesions precipitating retention: 
cathckd:wtiorl 
History of menstr-._ml irregularity; negative 
pregnancy test; unilateral mass; physical 0r 
laboratory evidence of hormonal abnormaEties; 
sonography, lilparoscopy, tissue diagnosis 
As above with bilaterd ovari;m enlargement 
History of sexual activity; pregnancy test may 
or may not be positive; sonography. may or 
may not have pain or tenderness; may present 
as ;::cute emergency 
History and findings compatible with pelvic 
I int1ammatOl)' disease; sonography, laparos,~opy 
I 
I History of-pain or asymptoma.tir; mrilatcra! 
!rilass; maybe very large; sonography, 
'aparo~>eopy , Lissuc diagnosis 
1vianagemen.t ofendometriosis 
Endom(;triosis is n complex and perplexing (;ondition 
rha:t should be managed in cunsultation ·vvith a 
gynecologist Th~~re arc many treatment pptions and 
tl1ese are listed in Table 22. NSA1Ds (Table 17) are 
usually not beneficial k females wlth endometriosis 
while horrnonal medications may be useful m 
Ado!escentjema!e menstrual disor·ders 
reducing (even removing) non--uterine endometrioiic 
!issue. Clinicians can use ora] contraccpt.}vcs, patch 
contraception, transvaginal horm.onal contraccptivt~s_, 
dcpo-medrpxy~progesterone acetate (DMPA: 1 ,'5-D mg 
in1ratnuscu1arly every three months), or oral mcdroxy-
progcsten:nic acetate (30--50 mg once a day). Adverse 
effects of proge~tins h:clude ineg1..:lar bl~eding, 
bloating, weight gain, and others. lf combined oral 
cQntraceptives are ctmtraindi.cated, ene may use a 
progestin-domin<mt oral conh-ae~ptivc. 
Oral contracepti;~~---·-·······-····-··········-······--·-·-·-·······-····-·--···- -------------~----l 
Medroxyprogestcrone acetate (Provera or Depo-Provera) 
Androgens (methyltestQsteroue) 
Gonadotrop.in-rd~asing hormone agonlsts (let:lpro!id(~ acetate or n.afarelin acetate) 1 
. i Danazol (danocrure) j 
... J\nastrczol3 (/\.ri:n~de~) I 
Laparoscopic ablation i 
UTN.A 0-a&er Utcrosacrai Nerve Ablation) ! 
Electrocautery 
Tnermocoagulati.on 
Lapa,roton~y with resection of endometriomas 
Presacral ·neurectomy 
! Correctio:r; of associated congenital reproductive anoma_l::i:.e;:s _______ ......,.--::----:-""7."--:---:----::-:--..J 
.;.*Modified ,viti~--pe;:;;~-i~~i;~---i~,;;.;:-;~·-6i-.~yd·,~n~-;~·-·i)}i:--<5;;~~~:··rii... ,. Tsitsika AK, Patd DR: Mtmstrual disorders .in adolescent 
females.: Current concepts. Dis-A-Mm;th 2009; 55(2): pag.c 104. 
Gonadotropin-releasing hormone .agonists (leuprolide 
acetate or nafarelin acetate} can also be prescribed by 
themselves or in combined with estrogen. The 
addition of estrogen can help prevent the reversibie 
state of menopause with amenorrhea, h.ot Gashes, 
vaginal dryne:.-s, and loss of bone mass. "If these 
agonist:s are used, they are usually stopped after 6 
months unless estrogen is added to permit an 
additional 6 months use due tu bone loss assodated 
with. GnRH agc>nist 
Arom~ttase inhibitors (anasaxo1e) are used to trca.t 
pnst.menapau~al breast cancer but can be used for 
adults with endometriosis; it may be combined v-iith 
oral contraceptives or GnRh. This may be .an option 
for women who have not had succcs~ with other 
treatment o.r are unable to use other treatment 
modalities, 
Surgical management is also useful for many with 
endometriosis as noted in Table 22 and hormonal 
management can be co:rrtinued after surg;~ry to control 
the development of endometriosis that may occur 
after surgical treatment. Prcsetvatim1 of fertility is 
also the goa) of any surgical procedure in the 
treatment of endometriosis. 
.Premenstrual syndrome 
Prerm:-nsuuaJ syndrome (PMS) includes various 
symptoms (see Table 23) that typically initiate during 
the latter luteal phase just before the onset of the 
menstrual flow and tend to resolve with the initiation 
of rnensirua1 flow (Table 3). Most reproducdv::: 
l'emales report P MS fea;ture.s and. up to 8% note severe 
emotional syn:ptorns (Le., anxiet)'; depres~ion, failure 
to per[or dally activities) tha,t meet the American 
Psychiatric Association's criteria. for Premenstrual 
Dysphoric Disorder (PMDD) (25,26). Vatious 
theories an; proposed lor PMS, though the precise 
cause (s) a:re not known at this time (Table 2!;). 
A careful evaluatkm is necessary to differentiate 
PMS from su.ch conditions as chronic fatigue 
syndrome, anemia., diabetes mellitus, hypothyrodism, 
collagen va1;cular disorders, and others. Adding to the 
confu~ion are the various cond.itlong that may be 
worsened by me11struation; th{~5e includ~! migraine 
headaches, erythema rnuitiform c, acut~ inte1'mittent 
porphyria, rheumatoid arthritis, .recurrent ar;~phyluxis, 
and ~he three ''periodic'' condl;ions······periodic fever, 
paralysis, and hypersomnia.. 
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Table 24 . . Proposed T!:wori;:sfu1· PMS 
[ 
... Dysfu~~~on o.f serotnnin or·-;·~~_~·.·_' rm,buty.ri c ~~;~i"A._ . .. (0~\j3:~\--A )--
t sens1t;v1ty to 1"\ydroxy~tT)'ptamm e 1,5-H I) recertqrs 
_____________ , ................ 
{with{. with red~ced llWel.s and impaired uptake ofseratQnin) 
! Anx1ety: dysfunctionaJ interaction ofm.~tabotites of progesterone and receptors ef 
) j'--artlinoh\ltyric acid A (GABA-A) receptors 
! Panic Attacks_: i lutt:t~) pha.~;e levels of Pcy2 
r mpa<~tof recm:-ent episodes v<ith i :mn:>itization and more PMS symptoms 
1 
! 
Complex and pt:rj."ilexing !r.terplay bet'w~en various chemicals and sysfems: i 
.. prostaglandins, en0.ogenous opioid pcptides, serotonin (other central _jl 
! .. nervous sysl~:m neurotr<mstnitters). ovarian steroids, and the peliphera] 
l * autonomic nervous svstem 
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Afano.gement ofPMS 
Various supportive measures Hre typically 
recommended for PMS .sy.mptoms including regular 
exercise, healthy sleep--wake cycles, regular hot baths, 
reduced salt intt.!ke, reduced intake of cuffeinated 
b ( 4 ,,,. d'· t' everages 01,.cn mg;1 m a o;escen SJ, improved 
nutrition {1.vith less sugar), abstinenc{~ fl'cm alcohol, 
and reduction in excessive stress. NSAIDs may 
improve breast or pelvic pain noted in some with 
PMS, v.,·llile diuretics (such as spironolactone or 
hydrochlorothiazide) may reHevc symptoms due to 
PMS weight gain or edema; abuse of diuretics, 
however, may lead to increased \:veight gain from 
increased edema. 
1vfeasures often suggest.ed but without su.pportive 
research include herbal or vitamin supplementation, 
Stldi measures attempted, but without specific 
research to vedf): benefit, include oral contraceptiv>:s, 
progesterone, thyroid horrnone supplementation, 
lithium, evening primrose o!l, atenoJol, ptostaglandin 
inhibitors, vitarr~in E ot B6 supplementation, and 
supplemenm.tion with calcium or magnesium. 
Management of symptomatic anxit:ty or 
depression (or mental health disorders) is important. 
PMS emotional features (table 23) may show some 
improvement with the judicious t:se of sele<.:tive 
serotonitl reuptake inhibitors (SSRis), such as 
scrtra!ine (50 mg dai!y), fluoxctine {20 mg daily), or 
paroxetine (20 mg daily). Those with excessive 
symptoms of anxiety may benefit from prescription of 
anxiolytics wch as alpra.zolam or buspirone. Some 
c1in~cians have used tricyclic antidepressants (such as 
clomipramine), t110ugh great care should be exercised. 
m prescribing 1ticyc1k antidepressants (TCAs) to 
adolescents due to the m1my side effects (27)-
Meastrres used for adults with severe PMS 
include gonadotTopin-releasing hormone (GnRH) 
agonists (such as leuprolide [Lupron] and buserelin 
[Suprefact]), These agents produce a l:nedical 
oophorectomy by "uppression of gonadotropin release 
with resultant prevention cf ovuiation and ovarian 
hormone production. Adult females with severe 
mastalgia as parL of their FMS have been prescribed 
bromocriptine, a doparnine-receptor agonist. 
Conclusion 
1\-fenstrua! disorders are cummon in the adolescent 
female, 111is paper reviewed basic concepts of 
menstrual disorders in adolescents beginning with an 
overview of menstrual physiology followed by 
cons!den:Jion of v«ri0us abnormal mcm.truaJ patterns: 
artJenmthea (primary and secondary), dysfunctional 
uterine bk:cdiog, dysmenorrhea (primary and 
secondary), and premenstrual syndrome. 
Acknowledgn:lents 
This paper is an adapted version of a chapter i.n the 
book "Adolescent medicine: Pharmacothet'apeutks in 
general, mental a.n.q sexuar health" edited by Donald E 
Greydanus, Dllip R Patel, Cynthia Feucht, D<:nim A 
Oma:·, Joav Merrick and published w·ith pem1issi<.Jn 
by Walter de Gruyter, Berlin and New York, 
ll! Gre:ydanus DE. Breast and gynecologic diS()f<.krs, ln: 
!Intinan:> AD, Greydanus DE, eds. Adolew:nt 
medicin:::, 3;-d ed. Nor<.valk, CT: Applctm1 l.angc, 
1997 :520·34. 
[21 Grt:ydanus DE, Tsistika AK .. Q[,ins M.T. Th~ gyn<:cology 
system and lhe adokst-enl. In: Grej'danus DE. Feinberg 
AN. Patel DR, HamniGk DN , eds. Th~ pedbtril~ 
diagnostic exwninatirm. New York- \':,~(}rav,'-liill, 
2003:70). 18. 
PJ Greydanm DE, Omar H.A, Tsilsik.a AK, Patel DR. 
Mcnstru<Ji discrders in adolescent females. In: Omar 
H.A, Greydanus DE, Tsitsika A, Pate! DR, tvkrri<:k J, 
e.ds .. PecHattic and adoJescent sextmhty and gynecology. 
Prindpks lor the primary care did.cian. New Yodc 
·N!::va Science~. 2010:317.,411 
i'li Greydanus DE, Omi:li HA, T.~1tsika AK, Patel DR. 
:Yl.e'l~trc~sl disonk:rs in adoiescer:t females. Cwx 
Concc:pts !)i,-A-Month 2(';09; 55(2):39·114. 
f5] GrcydamJ.S DE, Tsitsika A. Spcdal considemtions f<>r 
the fcmak athlete. In: Patd DR. Greydan.us DE, Baker 
R, cd$. Pediatric practi•~~= Sports rr:.~lii,~ine. New York: 
McGra'N-Hill, 2009:&6-!01. 
j_6] CNydanas DK. P<ltd DR. Medical a~pect$ Gf ihc.; female 
athlete at pllber1y. Int Spc1rts Med .1 2()04;3(1 ): 1-25 .. 
["' Greenfield TP, Blythe MJ. Menstrual disorders in 
addcsccnts. In: Grcyd.m1us DE. PateL DK Pratt HD, 
eds. Essential adolescent medicine. New York: 
t\kGraw-Hill, 2006:591-612. 
378 Donald.E Cireydanus, Shawn .)'orrel, l!atim A Orrmr. et<tl. 
!8] Harber \ '.L Mcilstrual cytk changes in c<l:dd!c women: 
A r~v)ew. !nt Sports Med J 2004;5: 5.6 .. 66 . 
{9) DtJitch HR, Hillnrd PJ.. Menstmal disorders in th(o 
ruHege age female. Pediatr Clirr North /\rn 
2005;52; 10 l-25. 
[1 01 M anore M~\'1. N utritionaJ recotru"'<.cndaiions and athtctic 
menstrual dysfi.mc:ti0n_ 1nt Spurls Med J 7.004;5:45-55. 
[ ll) DustJk T. Higil intensity training and mcmirual cydc 
disorder:; in athl:: t.e~ . bt Sports Med. J 2.0.04;5:37-44. 
f.l 2] Greydrutus DE, Pate l DR. The female aUJlete: befun: 
and b<:y<.md puberty. Pediatr Gin. North Am 
2002;49 :553-&0. 
[13.j American Academy ofPcdiatr.irs: Medical Ci..>n"'~rns in 
the tcmak s.thlett' .. P:~diatri~;s 2000, 106:610·3. 
[ 14J Guz!ck DS. Polycysllc ovary syndrome Obstet Gyncwl 
2004; 103:181·91. 
[151 K:1lkami R, Gem R, Scott-Emua...'<pm .A.B. Adolescent 
hematology. fn : Greydarms DE, P~1t~i DR. Pratt UD, 
eds. E~semial adolescent medicine. Nt'lw Y(r<'k: 
McGra'I.V·Hill, 2.006:11! .. 45. 
[ 16 J }-;'.riberg< B~ Orno }\.K, Lindgren }'\~ T_.,~th~gen S. Ii tecding 
di~orders <tmong young )'Omen: A population-based 
prcvdcnce smdy. t\cta Obstet Gync;,:d Scand 
2006;85(2):200-6. 
{l?] Mat)1sina LA Zol()to EV, Sinenko 'LV, Grcydanus DE. 
Dysft~nctional uterine bleedin.g inado~escent~ :. Conc-..pt~ 
of pathophysiology anci managcmenl. p:riin Ca;-~; Gin 
Office Pract 2006;33(2) 50:1 -15. 
11 8] Strickland JL, WaH JW. Abttormal utcr:in~:: bleeding in 
actDlcsccnls. Obs:.:et Gynecol Clin !'~orth Am 
2003 ;30(2):3 21 ·35, 
[l9J Clu~%ei;s EA, Cowe!l Ck Acut(: r:do!escent 
n\~n.orrhagia. Am J Ohstct Gyneco\1981 ;139: 2.77~82 .. 
[20j Ortil Ml, Rl"Jlge!··Florcs E, Carillu-Alare<)n LC, Vcras-
Godt1y HA. Pr~va!cnce and impac;: o f primary 
i!y~mcnorrh~a among :tvfexicao high ,;d~ool students. Int 
.T Gynaccol O:bstet 2009:107(1):240-1. 
[21] Ortiz lvil . Prim~y dysmctK:rthca{ amcrtg M<~xir.a.n 
t:niversity students: Ptevalcncc, impact, and treatment. 
Eu.rJ Ohstet Gyne.col Rcpmd Biol20 iO:l52(1):73-7. 
[22J Dawonn MY. DysmcJ1oitho.clt and prMt.agiandins: 
pharmacalogicd a."'d t.~erapeutic considerations. D!:uy,:; 
1981 :22(1 ):42-56. 
[23) D.awood ~IY. Primary ctysmcn.orrh.:al: Advances in 
pathogenesis anJ managcmtmt. Qb~tet Gynccol 
2006; 10&(2):428-41. 
!241 Wu MH, Lu C\:V, Chuang PC, Ts.ai SJ. Pro:>tuglandi.n 
U2: TI1c. mus-o.er of cnJomi.ctrlosis? Exp Biot Med 
20!0)3 5(6):668-77. 
f25] Amcri~.:iul Psychi~.tricAssociatioi1. DSM:-IV: Dia.g.t;ostic 
and stru:isti.cal m:a..'1uat of mental discr.dt!:s, 4th cd. 
\Vnshington, DC: American Psy chia!ric Ass(idation. 
1994. 
[26i American Psychia:.:ic A~sociation. DSM-lV-TR: 
Diagnost.i.c and ~1,1t!s;jcttJ rnanual of m~ntar disord.ers .. 
4!h ed, teJ<t rev. Vhlshh1gtcn, DC: Americm1 Ps:ychiairk 
Association, ~wou. 
[27] Greydanus DE, Caiks J, Patel DR. l'<:diatric and 
adolc~cen.• psychoph!mnacnlogy A practical manual for 
p~diatrlcians: Cembridgc: Camhridgc University Press, 
2008. 
Submitted: Ootober 02, 2011. Re:;ised:· Nnve<r.hcr \6, 
201 L Accepted.: Dec<Jmbcr 01 , 2011 . 
'' , ' , ', ', ' '', ', ' , ', ' ', ' ', ' ~~·~~~::~~~: 
